Skip to main content

Advertisement

Table 5 Multivariate logistic analysis of the relationship between medications used with statins and high MDA-LDL level

From: Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease

  Adjusted OR (95% CI) p
ACE-Is or ARBs 1.29 (0.61–2.78) 0.508
β-Blockers 1.04 (0.51–2.12) 0.923
Ca channel blockers 1.23 (0.62–2.45) 0.548
Metformin 0.48 (0.24–0.94) 0.032
Pioglitazone 0.61 (0.28–1.28) 0.190
α-Glucosidase inhibitors 0.43 (0.21–0.87) 0.018
Sulfonylurea 1.65 (0.76–3.66) 0.205
Insulin therapy 0.51 (0.21–1.20) 0.124
Other variables   
 LDL cholesterol 241.6 (22.0–3289.8)* <0.0001
 Triglycerides 12.95 (2.02–93.09)* 0.007
 HDL cholesterol 0.10 (0.00–0.98)* 0.048
 Adiponectin 1.18 (0.19–7.12)* 0.859
  1. Abbreviations: ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CI confidence interval; HDL high-density lipoprotein, LDL low-density lipoprotein, MDA-LDL malondialdehyde-modified LDL, OR odds ratio.
  2. Multivariate logistic regression analysis was performed with an adjustment for all indicated medicines and the levels of LDL cholesterol, triglycerides, HDL cholesterol, and adiponectin. A high MDA-LDL level was defined by a median value of >91 U/L.
  3. *Range OR (95% CI).